The Oncology Institute of Hope & Innovation Celebrates 50th Practice Location

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) — The Oncology Institute of Hope & Innovation (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, recently commemorated the opening of their 50th nationwide clinic with a ribbon-cutting ceremony and celebration at the newest location in Hillcrest neighborhood of San Diego, California.

Chief Operations Officer Daniel Virnich, MD, MBA, welcomed guests with remarks detailing TOI’s mission of offering comprehensive, personalized cancer care in the local community. TOI physician and Medical Director Dr. Phillip Saunders also spoke about how TOI is uniquely positioned to provide patient-centric care.

“We are honored to open our 50th location in Hillcrest and bring TOI’s state-of-the-art oncology care to new communities across the country,” stated Dr. Virnich. Dr. Saunders added “At TOI, each patient receives tailored, innovative treatments administered with the utmost compassion and concern. We look forward to welcoming the residents of San Diego County to our newest location.”

Founded in 2007, TOI is one of the largest value-based oncology practices in the U.S., taking accountability for both the quality of outcomes as well as the medical costs associated with a population of more than 1.5 million patients. They offer a diverse set of cutting-edge resources including:

  • A leading clinical research program offering patients access to more than 130 clinical trials.
  • Comprehensive dispensary services to offer convenience and savings to patients receiving oral chemotherapeutics.
  • A care management program which helps patients navigate a complex health care system.
  • A state-of-the-art website with educational resources, scheduling capabilities, and a convenient patient portal.

“Our patient-centric model improves patient satisfaction and quality of life, ultimately reducing the financial burden on both patients and the broader healthcare system through lower drug costs, reduced hospitalizations, and appropriate incorporation of end-of-life care,” added Dr. Virnich. “This milestone brings us one step closer to expanding this innovative model across the country.”

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Read the official press release here.

 

World-class cancer care close to home

Request an appointment at a clinic near you

First Oncology Specialist Goes Public via SPAC

Article written by Tara Bannow via Modern Healthcare

The first publicly traded oncology specialist debuted on the stock market this week following its merger with a special purpose acquisition company.

The Oncology Institute, a provider with 50 offices in four states headquartered in the Los Angeles area, closed on its combination with DFP Healthcare Acquisitions Corp. and is now trading on NASDAQ under the ticker symbols “TOI” and “TOIIW.” The company’s stock is currently valued at about $8.50, down more than 18% from its initial value on Monday.

Founded in 2007, TOI touts a brand of value-based oncology care its leaders say is lacking in the current cancer treatment industry, which is mostly delivered on a fee-for-service basis. Brad Hively, the company’s CEO, said TOI manages more than 1.5 million patients under value-based contracts, which comprise a little over half of its revenue. Of the 1.5 million patients, about half are covered by managed Medicaid, followed by commercially insurance and then Medicare Advantage. The other roughly half of TOI’s revenue is fee-for-service.

Click here to subscribe to read the full article: https://www.modernhealthcare.com/finance/first-oncology-specialist-goes-public-spac

The Oncology Institute of Hope & Innovation Adds Los Angeles Practices to Network

TOI is excited to welcome additional physicians to its team of 80+ employed clinicians

LOS ANGELES, Nov. 17, 2021 (GLOBE NEWSWIRE) — The Oncology Institute for Hope and Innovation (TOI), one of the largest value-based community oncology groups in the United States, recently acquired the practices of Ellsworth R. Grant, MD, and Leo E. Orr, MD, expanding TOI’s network of more than 80 specially trained physicians and advanced practice providers.

“By joining with TOI, I can continue to provide personalized care to my patients while leveraging TOI’s outstanding medical resources,” Dr. Grant stated. Dr. Orr agreed, adding, “I am proud to join such a well-respected group of practitioners with a powerful reputation for cutting-edge care.”

The new Westlake facility will provide patients with the same advanced medical services and health care available to patients at all TOI locations.

The office is located at:
1245 Wilshire Blvd, Suite 801
Los Angeles, CA 90017
Call (213) 481-3948 for appointments.

Founded in 2007, TOI is one of the largest value-based oncology practices in the U.S., taking accountability for both the quality outcomes as well as the medical costs associated with a population of more than 1.5 million patients. They offer a diverse set of cutting-edge resources including:

  • A leading clinical research program offering patients access to more than 130 clinical trials.
  • Comprehensive dispensary services to offer convenience and savings to patients receiving oral chemotherapeutics.
  • A care management program which helps patients navigate a complex health care system.
  • A state-of-the-art website with educational resources, scheduling capabilities, and a convenient patient portal.

“We are excited to add Drs. Grant and Orr to TOI’s growing team of premier oncologists. Both physicians bring a wealth of medical knowledge and will provide outstanding care for our patients,” TOI COO Dr. Daniel Virnich remarked.

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, the expectation that the Company’s common stock will begin trading on Nasdaq, and the anticipated benefits of the business combination. These statements are based on various assumptions and on the current expectations of DFP and The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DFP and The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the combined company or the expected benefits of the business combination; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the combined company’s business; those factors discussed in the documents of DFP or TOI filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DFP nor The Oncology Institute presently know or that DFP and The Oncology Institute currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DFP’s and The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. DFP and The Oncology Institute anticipate that subsequent events and developments will cause DFP’s and The Oncology Institute’s assessments to change. DFP and The Oncology Institute do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing DFP’s and The Oncology Institute’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

World-class cancer care close to home

Request an appointment at a clinic near you

The Oncology Institute Completes Business Combination with DFP Healthcare Acquisitions Corp. to Become Publicly-Traded Company

NEW YORK and LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) — The Oncology Institute (“TOI” or “The Company”), the U.S. market leader in value-based oncology care, announced today that it has closed its previously announced business combination with DFP Healthcare Acquisitions Corp. (“DFPH”). The transaction was approved at a special meeting of DFP’s stockholders on November 12, 2021.

The combined company was renamed “The Oncology Institute” and will be led by its existing management team. Its shares of common stock and warrants began trading today on NASDAQ under the new ticker symbols “TOI” and “TOIIW”.

The transaction implies an enterprise value for TOI of $842 million. In connection with the transaction, TOI raised approximately $334 million of cash proceeds, which includes $275 million from a previously announced private placement of common stock (the “PIPE”). Of that $334 million, approximately $133 million will be retained on TOI’s balance sheet to fund growth initiatives, including de novo clinics and acquisitions.

“Today is an incredibly proud moment for TOI and a key milestone for the industry at large,” said Brad Hively, CEO of The Oncology Institute. “We are leading the shift to value-based oncology care by deploying a scalable and replicable operating model to disrupt the $200 billion US oncology market. Since our founding in 2007, we have provided high-quality cancer care to more than 150,000 patients in 50 locations across California, Nevada, Arizona, and Florida. We would not have reached this important milestone were it not for the dedication and hard work of our teammates throughout the country. As a public company, we look forward to bringing our proven model of individualized care plans, evidence-based medicine, and great symptom control to more patients throughout the nation.”

Richard Barasch, Chairman at DFP Healthcare Acquisitions, comments, “TOI is the leader of value-based oncology care. We were attracted to TOI for its high-touch, data-driven approach, strong leadership, and track record of patient satisfaction, which is disrupting the status quo in cancer care. We are excited to close this transaction, and I look forward to continuing to work alongside Brad and the management team to make high-quality, affordable cancer care a reality.”

The Oncology Institute’s new board of directors will be comprised of seven directors, including: Richard Barasch, Brad Hively, Karen Johnson, Mo Kaushal, Anne McGeorge, Maeve O’Meara, and Ravi Sarin. TOI’s management team will continue to be led by Brad Hively, Chief Executive Officer; Dr. Daniel Virnich, Chief Operating Officer; Scott Dalgleish, Chief Financial Officer; and Dr. Matt Miller, Chief Administrative Officer.

Advisors

Jefferies LLC acted as lead financial advisor and Guggenheim Securities, LLC acted as financial advisor to The Oncology Institute. Deutsche Bank Securities Inc. and UBS Investment Bank acted as financial advisors to DFP. Deutsche Bank Securities Inc., Jefferies LLC and UBS Investment Bank acted as capital markets advisors to DFP. Latham & Watkins LLP acted as legal advisor to The Oncology Institute, White & Case LLP and Polsinelli PC acted as legal advisors to DFP, and Katten Muchin Rosenman LLP acted as legal advisor to Deerfield. Deutsche Bank Securities Inc., Jefferies LLC, UBS Investment Bank and Guggenheim Securities, LLC, acted as placement agents on the PIPE and Sidley Austin LLP acted as legal counsel to the placement agents.

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

About DFP Healthcare Acquisitions Corp.

DFP Healthcare Acquisitions Corp. (DFPH) was a blank check company whose business purpose was to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. DFPH’s sponsor was an affiliate of Deerfield Management Company, L.P., an investment firm focused exclusively on the healthcare industry, and Richard Barasch.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, the expectation that the Company’s common stock will begin trading on Nasdaq, and the anticipated benefits of the business combination. These statements are based on various assumptions and on the current expectations of DFP and The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DFP and The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the combined company or the expected benefits of the business combination; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the combined company’s business; those factors discussed in the documents of DFP or TOI filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DFP nor The Oncology Institute presently know or that DFP and The Oncology Institute currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DFP’s and The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. DFP and The Oncology Institute anticipate that subsequent events and developments will cause DFP’s and The Oncology Institute’s assessments to change. DFP and The Oncology Institute do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing DFP’s and The Oncology Institute’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

TOI’s General Counsel, Mark Hueppelsheuser, Nominated for LABJ 2021 Leaders in Law Awards

The Oncology Institute of Hope and Innovation is proud to announce that Mark Hueppelsheuser, ESQ, General Counsel, has been nominated as an in-house counsel nominee for the Los Angeles Business Journal’s 2021 Leaders in Law Awards.

These awards honor the significant role that in-house counsel plays in the success of their organization, as well as recognizes the achievements of leading attorneys and firms within the Los Angeles business community. Each nomination category will recognize candidates for their exceptional legal skill and achievement across the full spectrum of responsibility, exemplary leadership, and contributions to the Los Angeles community at large.

Hueppelsheuser has served as The Oncology Institute’s general counsel since 2015 and has played a key role in the practice’s unprecedented growth and improvement in that time. Over the past several years Mark has created and enforced a robust and highly vetted compliance program, managed numerous practice acquisitions, industry-leading external counsel, private equity investments in the practice and, most recently, The Oncology Institute’s efforts to successfully take the practice public to create further growth and an improved patient experience.

Prior to joining The Oncology Institute Mark earned his B.Sc at The University of Alberta with a dream to serve patients in the health care space. Mark then completed his J.D. at Chapman University’s School of Law, going on to earn his LL.M at America’s top legal dispute resolution program, Pepperdine Law School’s Strauss Institute. During that time, Mark gained experience in civil litigation and went on to become a member of Quiksilver’s legal team, reporting directly to the global general counsel and helping to manage the legal responsibilities of a multi-billion dollar global enterprise. Mark is also proud to have volunteered countless hours over several years successfully mediating contentious cases in the Orange and Riverside courthouses in an effort to give back to the community he is proud to call home. 

Nominees will be honored, and finalist and winners will be announced on Wednesday, November 17th at a virtual award ceremony.

The Oncology Institute of Hope and Innovation Exceeded Quality Standards and Saved Medicare More Than $1M in 2020

CERRITOS, Calif., November 1, 2021–(BUSINESS WIRE)–The Oncology Institute of Hope and Innovation (TOI), one of the largest community oncology practices in the US and one of the nation’s leading value-based oncology services platforms, saved Medicare more than $1M in 2020 as part of the Oncology Care Model (OCM) program, which equates to more than $3,000 per patient episode. This is in addition to the nearly $5M TOI has saved Medicare since the inception of the program. At the same time, TOI has continued to perform well on OCM’s Quality Measures, with above-average performance based on TOI’s aggregate quality score during the most recent reporting period (PP8). This exceptional performance again validates TOI’s track record of achieving better outcomes for patients, at lower costs.

In 2015, The Center for Medicare & Medicaid Innovation launched new payment and delivery models like OCM to improve the efficacy and efficiency of specialty care. The Oncology Care Model aimed to provide greater quality, highly coordinated oncology care at the same or lower cost to Medicare. Under the OCM, TOI entered into payment arrangements that include financial and clinical accountability for episodes of care surrounding cancer treatment. As an OCM participant, TOI provides enhanced services to Medicare beneficiaries such as care coordination, navigation, and 24/7 symptom management.

“We are extremely proud of these results and see them as validation of our approach to patient care,” remarked TOI CEO Brad Hively. “While traditional Medicare patients make up a relatively small percentage of our total patient population, we apply many of the same quality and cost-saving measures across the entire practice.”

The OCM is a natural extension of TOI’s value-based oncology care model. Staffed by a clinical team that speaks more than 20 languages, TOI offers in-house labs, transfusions, and dispensary services as well as cutting-edge treatments including an outpatient stem cell transplant program and access to more than 130 clinical trials. Believing that every patient deserves access to world-class care close to home, The Oncology Institute currently manages 50 community-based practice locations in California, Nevada, Arizona, and Florida. TOI serves approximately 1.5 million lives and treats more than 46,000 patients each year.

Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views and policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this agreement.

To read the full press release announcement, click here.

DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute

Special Meeting of Stockholders Scheduled for November 12, 2021

NEW YORK, October 22, 2021–(BUSINESS WIRE)–DFP Healthcare Acquisitions Corp. (“DFP”) (Nasdaq: DFPH) announced today that it has scheduled the special meeting of its stockholders (the “Special Meeting”) for November 12, 2021 at 10:00 a.m., Eastern Time, to approve the proposed business combination (the “Business Combination”) with The Oncology Institute (“TOI” or the “Company”), the U.S. market leader in providing value-based oncology care.

DFP also announced that it has filed its definitive proxy statement/prospectus for the Special Meeting and has commenced mailing the definitive proxy statement/prospectus to its stockholders of record as of September 23, 2021, the record date for the Special Meeting (the “Record Date”). The closing of the Business Combination is subject to approval by DFP’s stockholders and the satisfaction of other customary closing conditions and is expected to close as soon as practicable following the Special Meeting.

Your vote is important no matter how many shares you own. You are encouraged to submit your vote as soon as possible. If you hold your shares in “street name,” meaning that your shares are held at an account at a brokerage firm, bank or other similar agent, you may vote prior to the Special Meeting by using your voting control number and instructions provided to you by your brokerage firm, bank or other similar agent. Please contact your brokerage firm, bank or other similar agent to ensure your shares are voted. If you are a stockholder of record, you may vote prior to the Special Meeting by signing, dating, and mailing your proxy card in the return envelope provided with your proxy material.

If any DFP stockholder has any questions, needs assistance in voting their shares or does not receive the Proxy Statement, that stockholder should contact their broker or Morrow Sodali, DFP’s proxy solicitor, at (800) 662-5200, or by email to DFPH.info@investor.morrowsodali.com.

To view the full press release announcement, click here.

Dr. John Khoury Receives 40 Under 40 in Cancer Award

The Oncology Institute (TOI) is proud to announce that Dr. John Khoury was recently awarded the “40 Under 40 in Cancer” distinguishment by the Association for Value-Based Cancer Care. 

“It’s an honor to be placed in such distinguished list among many other great young oncology professionals and leaders who work very hard to improve the lives of those affected by cancer,” said Dr. Khoury.  

Dr. John Khoury is a triple board-certified physician who joined The Oncology Institute in 2020. He received his medical education at the University of Tishreen University Faculty of Medicine in Latakia, Syria. He then went on to complete his residency and fellowship at Oakland University William Beaumont School of Medicine in Detroit, where he specialized in hematology and oncology. 

Dr. Khoury never misses an opportunity to mentor and advise his fellow physicians at The Oncology Institute and encourages them to think outside the box. He currently serves as the Principal Investigator for several clinical trials at TOI. His patients describe him as “knowledgeable, patient, and happily explains things in terms [they] can understand.” Dr. Khoury understands the importance of family and understands how important it is to not only effectively communicate with his patients but also their family members in order to reduce their concerns and answer their questions during a very difficult time. 

This award recognizes Dr. Khoury’s dedication to providing the best care to his patients and continuous efforts to put them first. He serves patients at TOI’s Glendale and Pasadena locations. 

The “40 Under 40 in Cancer” Award is presented by The Lynx Group, Upstream Partners, the Association for Value-Based Cancer Care, NCODA, and Swim Across America. 

To learn more about Dr. John Khoury, his work and to book an appointment, click here. 

World-class cancer care close to home

Request an appointment at a clinic near you

Introducing Scrubs the TOI Hero Bear

We’d like to introduce the newest member of the team – Scrubs, the TOI Hero Bear!

As part of The Oncology Institute’s League of Heroes, Scrubs’ mission is to help celebrate the upcoming opening of our 50th clinic location, scheduled for early November. In the meantime, he’ll be making his rounds at a few of our clinics across Southern California before he reaches his final destination.

Follow his journey across our social media channels in the coming weeks!

Facebook Circle Logo Twitter Circle Logo LinkedIn Circle Logo

World-Class Cancer Care Close to Home

Find a convenient clinic location near you

5 Fast Facts: Ovarian Cancer

September is Ovarian Cancer Awareness Month. According to the American Cancer Society, a woman’s risk of getting ovarian cancer during their lifetime is about 1 in 78¹. In 2021 alone, it’s estimated that over 21,000 women will receive a new diagnosis of ovarian cancer.

As the month comes to a close, we invite you to take a few moments to educate yourself, learn about the early signs and symptoms of ovarian cancer as well as how to be proactive.

  1. Signs and Symptoms
    • Abnormal vaginal bleeding (Especially if you’re past menopause) 
    • Pain or pressure in the pelvic area 
    • Abdominal or back pain 
    • Bloating, feeling full too quickly, or difficulty eating 
    • A change in bathroom frequency, such as the urgent need to urinate and/or constipation.

2. Risk Factors for Ovarian Cancer Include: 

    • Being middle-aged or older
    • Genetics: If someone in your immediate has had ovarian cancer 
    • Breast, colon, or uterine cancer diagnosis
    • Endometriosis (Tissues that normally line your uterus grow on the outside)

3. Recent Findings 

Recent studies have found that ovarian cancer starts in cells at the tail ends of the fallopian tubesnot necessarily in the ovary itself ² – this new information may open more research studies looking at preventing and screening for this type of cancer.

4. Risk Reduction 

While there is no definite way to prevent ovarian cancer, below are some findings associated with lower risk. 

    • Having given birth and breastfeeding 
    • Taking oral contraceptives for 5 years or more 
    • Having had a tubal ligation (getting your tubes tied), both ovaries removed, or a hysterectomy (an operation in which the uterus, and sometimes the cervix, is removed)

5. Screening & Prevention

The Pap test only screens for cervical cancer and HPV, not ovarian cancer. Since there is not a specific screening test for gynecological cancers apart from cervical cancer, it is important to recognize the warning signs. Talk to your doctor if you are experiencing any of the symptoms associated with ovarian cancer. 

For more information and resources on ovarian cancer, visit the American Cancer Society’s website. 

References 

  1. Key Statistics for Ovarian Cancer, American Cancer Society
  2. Ovarian Cancer Causes, Risk Factors, and Prevention, American Cancer Society
  3. Ovarian Cancer, Centers for Disease Control and Prevention (CDC) 

With you through every phase of your cancer journey

Learn more about starting treatment at a location near you